Moleculin Biotech (MBRX) Competitors $2.74 +0.07 (+2.62%) (As of 03:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MBRX vs. DARE, ESLA, ICCC, PASG, ACST, PMN, LTRN, LIAN, ALTS, and CTXRShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Daré Bioscience (DARE), Estrella Immunopharma (ESLA), ImmuCell (ICCC), Passage Bio (PASG), Acasti Pharma (ACST), ProMIS Neurosciences (PMN), Lantern Pharma (LTRN), LianBio (LIAN), Janone (ALTS), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Daré Bioscience Estrella Immunopharma ImmuCell Passage Bio Acasti Pharma ProMIS Neurosciences Lantern Pharma LianBio Janone Citius Pharmaceuticals Moleculin Biotech (NASDAQ:MBRX) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has higher earnings and valuation, MBRX or DARE? Moleculin Biotech has higher earnings, but lower revenue than Daré Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$29.77MN/AN/ADaré Bioscience$2.81M9.94-$30.16M-$0.59-5.43 Does the media favor MBRX or DARE? In the previous week, Daré Bioscience had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 11 mentions for Daré Bioscience and 9 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.57 beat Daré Bioscience's score of 0.34 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daré Bioscience 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in MBRX or DARE? 15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are owned by institutional investors. 7.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 4.0% of Daré Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate MBRX or DARE? Moleculin Biotech currently has a consensus price target of $31.00, suggesting a potential upside of 1,031.39%. Daré Bioscience has a consensus price target of $24.00, suggesting a potential upside of 647.66%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Daré Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Daré Bioscience 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer MBRX or DARE? Daré Bioscience received 128 more outperform votes than Moleculin Biotech when rated by MarketBeat users. Likewise, 73.25% of users gave Daré Bioscience an outperform vote while only 50.78% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformMoleculin BiotechOutperform Votes22850.78% Underperform Votes22149.22% Daré BioscienceOutperform Votes35673.25% Underperform Votes13026.75% Which has more risk & volatility, MBRX or DARE? Moleculin Biotech has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Is MBRX or DARE more profitable? Moleculin Biotech has a net margin of 0.00% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -157.44% -97.16% Daré Bioscience -191.65%N/A -18.98% SummaryMoleculin Biotech beats Daré Bioscience on 9 of the 15 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.22M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5695.6214.26Price / SalesN/A371.591,217.1987.73Price / CashN/A52.5939.5936.27Price / Book1.1010.236.946.36Net Income-$29.77M$153.22M$118.89M$225.56M7 Day Performance-11.33%-1.36%-1.33%-0.10%1 Month Performance2.62%-6.81%-3.17%2.02%1 Year Performance-65.02%32.27%32.49%27.87% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech3.0386 of 5 stars$2.74+2.6%$31.00+1,031.4%-67.1%$8.22MN/A0.0020Analyst ForecastAnalyst RevisionDAREDaré Bioscience2.2167 of 5 stars$3.21+0.9%$24.00+647.7%-23.9%$27.93M$2.81M-5.3830ESLAEstrella Immunopharma0.6333 of 5 stars$0.90-2.2%N/A-33.5%$32.56MN/A-3.54N/AGap DownICCCImmuCell0.5117 of 5 stars$3.65+1.4%N/A-22.1%$32.52M$17.47M-7.2075PASGPassage Bio2.9606 of 5 stars$0.52+1.2%$9.00+1,630.8%-19.0%$32.12MN/A0.00130ACSTAcasti Pharma2.366 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432PMNProMIS Neurosciences1.1238 of 5 stars$0.96-3.5%N/A-30.8%$31.46M$10,000.000.006LTRNLantern Pharma1.0538 of 5 stars$2.91-1.0%N/A-27.0%$31.37MN/A0.0020Positive NewsLIANLianBio1.1282 of 5 stars$0.29flat$3.50+1,115.5%-93.1%$31.12MN/A-0.35110ALTSJanone1.2294 of 5 stars$2.19flatN/AN/A$30.81M$39.61M0.00170CTXRCitius Pharmaceuticals2.9724 of 5 stars$0.17+0.2%$4.00+2,248.8%-77.9%$30.78MN/A-0.7120Short Interest ↓High Trading Volume Related Companies and Tools Related Companies DARE Competitors ESLA Competitors ICCC Competitors PASG Competitors ACST Competitors PMN Competitors LTRN Competitors LIAN Competitors ALTS Competitors CTXR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MBRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
